newsfilter
← Latest News
GlobeNewswire·

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentationRASolute